Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

Amplia has released its Quarterly Activities and Cash Flow Report for the quarter ended 30 June 2023.

Completion of Cohort 2 and currently dosing Cohort 3 in the Phase 1b stage of the ACCENT trial

Reported exciting preclinical data showing AMP945 enhances the activity of an alternate treatment for pancreatic cancer called FOLFIRINOX, in a model of the disease

Initiated a study with CSIRO to explore topical delivery of our FAK inhibitors for wound healing

Announced the name narmafotinib for AMP945

Over the coming quarter, Amplia expects to report further progress in the ACCENT trial as we finalise dose selection for the Phase 2 portion of the trial.

Preclinical studies with AMP945 in additional indications are also underway to identify further clinical and commercial opportunities for the drug.

Click link below to read the full ASX Release.

Quarterly Activities and Cash Flow Report - 30 June 2023